March 1–31, 2026 · Executive Brief
Autoimmune Awareness Month 2026
Replace diagnostic drift with a coordinated route from unexplained patterns to owned follow-up.
The boardroom issue
Autoimmune conditions can cross organ systems, specialties, and episodes of care. When the organization stores each symptom in a separate queue, the patient becomes the only person carrying the longitudinal pattern. Leaders can reduce diagnostic drift by making pattern review, appropriate escalation, specialty coordination, navigation, and follow-up ownership visible as one operating route.
Leadership signal
Diagnostic drift is an operating-system problem, not only a knowledge problem.
Autoimmune Awareness Month can do more than increase familiarity with a broad category of conditions. For healthcare executives, it is a structured opportunity to examine what happens when a person has recurring, multisystem, or unexplained concerns that do not fit neatly inside one encounter. The central question is not whether every concern should produce an autoimmune diagnosis. It is whether the system can recognize a meaningful pattern, conduct an appropriate clinical assessment, reconsider the working explanation when evidence changes, and keep responsibility visible until there is a safe next step.
The conditions grouped under the autoimmune umbrella are heterogeneous. They differ in pathophysiology, presentation, test performance, urgency, treatment, and the specialties involved. Many common symptoms are nonspecific, and no universal screening test can confirm or exclude all autoimmune disease. Those realities make reliable clinical judgment more important, not less. They also create an executive responsibility: design a route that supports uncertainty without converting uncertainty into indefinite dismissal, indiscriminate testing, or unowned referrals.
Recent evidence shows how delays can accumulate before specialty review. A multicenter German study of 600 people referred with suspected rheumatic disease reported a median total diagnostic delay of 30 weeks. The median was 26 weeks among people ultimately classified with an inflammatory rheumatic disease and 35 weeks among those without one; only 17.7% of the full sample completed the pathway within 12 weeks. These medians are descriptive, not acceptable targets, and the three-center design limits generalization. The study is useful because it separates delay into stages and demonstrates that the period before specialist consultation is operationally measurable.[17]
A separate study of 100 people with rheumatoid arthritis in Tunisia reported median intervals of six months before general-practitioner consultation, 12 months before rheumatology consultation, 15.7 months before diagnosis, and 18 months before treatment. Rural residence, lack of insurance, and other access factors were associated with longer parts of the journey. Retrospective interviews and a single national setting constrain inference, but the sequence illustrates why a health system should not treat “referral placed” as the finish line.[18]
Delay also has a relational dimension. In two large patient-reported systemic autoimmune rheumatic disease cohorts, more than 80% of respondents who reported a prior psychosomatic or psychiatric misdiagnosis said the experience harmed their self-worth, and 72% said the words still upset them. The mixed-methods, self-reported design cannot establish how often the earlier diagnosis was clinically unreasonable, yet the persistent association with underreporting and care avoidance matters. Language that closes inquiry prematurely can become a future access barrier.[8]
Leaders should therefore resist two symmetrical errors. The first is premature closure: treating a current explanation, normal result, or specialty boundary as proof that no further review is needed. The second is indiscriminate escalation: implying that every unexplained symptom needs a broad autoimmune workup. A governed route avoids both. It specifies when a pattern merits review, who performs that review, what information must be assembled, how urgency is assessed, how alternative explanations remain visible, and who owns follow-up when the answer is not immediate.
Executive priority
Audit one pathway for recurring, multisystem, or unexplained concerns. Follow it from the first documented pattern through clinical review, specialty access, accepted next steps, and follow-up ownership. Measure delay by stage and examine where trust or access is lost.
Quantitative evidence chart
Digital interest exceeded real-world use in one rheumatology survey
Pattern recognition
Help clinicians see the longitudinal story without predetermining the diagnosis.
Most clinical records are optimized for encounters, problems, and specialties. A person’s actual experience may be distributed across years of primary care notes, urgent visits, laboratory trends, imaging, dermatology photographs, gastrointestinal symptoms, medication trials, pregnancy history, family observations, and functional changes. If no role is responsible for synthesis, each new clinician may receive a partial story. The person is then asked to reconstruct the pattern under time pressure, often while unwell.
A safe pattern-review process begins with neutral chronology. It can summarize onset, recurrence, duration, triggers, objective findings, treatments tried, response, functional effect, unresolved questions, and changes over time. It should distinguish patient-reported experience from verified results without devaluing either. It should also preserve alternative explanations. A pattern summary is not a self-diagnosis, a laboratory order set, or a shortcut around qualified assessment. Its purpose is to make relevant evidence easier to review and reduce avoidable repetition.
Bias can enter even when clinical information appears standardized. A 2026 randomized factorial survey presented 1,031 U.S. primary-care physicians with lupus vignettes that varied patient race and sex. Across conditions, 63.9% initially included systemic lupus erythematosus in the differential diagnosis, with variation by the patient characteristics shown. Because this was a hypothetical vignette study, it does not establish what happened to real patients or explain every diagnostic decision. It does show that equivalent clinical information may not produce equivalent recognition, which makes structured reconsideration and equity review legitimate quality concerns.[1]
Reconsideration should be triggered by evidence, not by a fixed number of visits. Examples might include a worsening or recurring cluster, objective findings that no longer fit the working explanation, new organ-system involvement, a treatment response that contradicts expectations, repeated acute-care use, or a clinician’s documented concern. The exact triggers need local clinical governance. They should tell the team when to pause and synthesize, not what diagnosis to assign.
The workflow also needs a closing loop. After review, the patient should know the working explanation, remaining uncertainty, tests or referrals that are and are not indicated, warning signs that require escalation, who will receive results, and when the next review will occur. When specialty referral is not indicated, the route should still identify the clinician responsible for symptoms and function. “Not autoimmune” is not a care plan, and “workup pending” is not ownership.
Care route
Turn an unexplained pattern into an appropriate, accepted, and owned next step.
A reliable route is more than a specialist directory. It connects clinical review, urgency, information readiness, referral fit, access requirements, acceptance, interim care, result communication, and reassessment. The route must also support the common outcome that no autoimmune diagnosis is established. A well-designed process is valuable because it improves the path through uncertainty, not because it maximizes referrals or diagnoses.
The first control is qualified triage. Some findings require urgent evaluation; others can be reviewed in routine care. This article cannot define those clinical thresholds. Local clinical leaders must specify the settings, qualified roles, escalation channels, documentation requirements, and after-hours response. The executive responsibility is to make the approved response reachable and auditable.
The second control is referral readiness. Receiving services may need a concise clinical question, chronology, relevant examination findings, completed first-line evaluation, medication history, prior records, and the reason for urgency. Requiring unnecessary work can delay access, while sending an incomplete referral can produce a decline and more repetition. Primary-care and specialty teams should agree on a minimum dataset that is clinically justified, proportionate, accessible, and updated when evidence changes.
The third control is acceptance. Claims research involving 2,526 U.S. patients with systemic autoimmune rheumatic disease-related interstitial lung disease found that a pulmonology encounter within 90 days was associated with an 18% higher likelihood of recorded diagnosis compared with no such early encounter. The association, expressed as a hazard ratio of 1.18 with a 95% confidence interval of 1.03 to 1.35, cannot prove that early pulmonology caused diagnosis, and the condition is highly specific. It nevertheless supports the operating principle that timely cross-specialty contact can matter when a condition spans domains.[7]
The fourth control is interim ownership. If the next appointment is weeks away, someone must remain responsible for current symptoms, pending results, medication questions, accommodations, and worsening concerns within the scope of their role. If the receiving service declines the referral, the decline reason should be structured and the referring team should receive an actionable alternative. A closed referral without a safe alternate path should appear as an exception, not disappear from the work queue.
The fifth control is reassessment. Autoimmune conditions may evolve, and a reasonable earlier decision can need revision when new evidence appears. The record should state which changes warrant renewed review and how the person can re-enter the route. This is different from ordering perpetual tests. It is a planned response to meaningful change.
Proposed process flow
From unexplained pattern to owned follow-up
Equity and trust
Design for the person most likely to be dismissed, delayed, or unable to reach the next service.
Equity failures can occur at every stage: whose symptoms are recognized, whose report is believed, whose record is complete, whose referral meets a specialist’s expectations, who can travel, who can take time away from work, who has broadband, who can use a portal, and who receives a comprehensible explanation. An equitable route does not assume the same instruction creates the same access.
Geography is one visible barrier. A 2025 Alberta study measured travel burden for people with rheumatoid arthritis. The overall median modeled travel time was 13 minutes to primary care and 34 minutes to rheumatology, but the median to rheumatology was 226 minutes for remote residents compared with 26 minutes for metropolitan residents, an 8.7-fold difference. Administrative and geographic data do not capture every appointment, weather condition, transportation resource, or person-level preference. Still, the magnitude demonstrates why a referral metric without travel burden can conceal unequal access.[13]
Research participation has a similar spatial pattern. A 2026 retrospective review of U.S. clinical studies for autoimmune skin disorders estimated that 40% of Americans lived more than 200 kilometers from the nearest study site, with greater distance for rural and American Indian populations. Clinical-trial geography is not the same as routine access, and the analysis spans 2005 through 2024. It should not be used to estimate ordinary specialty access. It does show how national availability can coexist with local inaccessibility.[3]
Trust requires more than proximity. In a 2026 cross-sectional survey of 301 adults with systemic autoimmune rheumatic diseases in Middle Eastern hospitals, 84.7% identified physicians as a source of health information and 50.2% used social media. Fear of stigma was reported by 32.2%, while 14.6% described feeling like a burden. These findings are self-reported and context-specific. They remind leaders that communication, disclosure, family support, and stigma are operational issues: a technically available service may remain inaccessible if a person does not feel safe explaining what is happening.[2]
A Latin American survey of 244 people with rheumatic diseases found widespread internet and smartphone use, but only a minority described using the internet specifically for health information, and trust varied by source. The cross-sectional, connected sample cannot represent everyone in the region. The executive lesson is to avoid a false choice between digital and human information. Provide validated, accessible content through the channels people use, then make a clinician or navigator available to interpret it in context.[10]
Measurement should therefore combine timeliness, acceptance, and experience. Stratify carefully by geography, payer, language, race and ethnicity, sex and gender where appropriate, age, disability access need, entry setting, and other locally relevant factors. Protect privacy and suppress small cells. When differences appear, pair the numbers with interviews, complaints, navigation notes, and community review. The purpose is to locate a system barrier, not assign deficit to a group.
Unranked qualitative fishbone
Conditions that can produce diagnostic drift
- Fragmented chronologyRelevant evidence is distributed across visits, settings, and specialties.
- Variable recognitionEquivalent information may be interpreted differently.
- Ambiguous ownershipNo role synthesizes the pattern or tracks the open question.
- Referral frictionRequirements, capacity, and decline reasons are unclear.
- Geographic burdenTravel time and local specialist availability differ.
- Trust and stigmaPrior dismissal or fear changes disclosure and help-seeking.
- Digital exclusionPortal, language, device, accessibility, and literacy needs are unmet.
- Weak feedback loopsResults, declines, and worsening concerns do not return to an owner.
Operating model
Coordinate around the open clinical question, not the organizational chart.
Multispecialty care can still be fragmented. A person may have excellent clinicians in rheumatology, gastroenterology, dermatology, pulmonology, pharmacy, rehabilitation, behavioral health, and primary care while receiving no single integrated plan. Integration is not the number of disciplines listed. It is the mechanism by which roles share a current problem definition, reconcile recommendations, communicate with the person, and resolve conflicts.
A Danish integrated rheumatology-gastroenterology clinic for people with multiple autoimmune diseases offers one descriptive example. Among 54 patients, the pre-integration record showed an average of 29.6 outpatient visits, and patients reported improved continuity in the integrated model. The single-clinic design and absence of a causal comparison mean the results cannot establish that integration reduced utilization or improved clinical outcomes. The model is operationally relevant because it colocated decision-making for people whose needs crossed two specialties.[4]
A 2025 integrated-care model for immune-mediated inflammatory diseases similarly described a structure that connected physicians, pharmacists, nurses, patients, and medical-director governance. The published report is a model description with limited outcome evaluation, so it should be treated as design evidence rather than proof of effectiveness. Its value lies in making leadership sponsorship, shared process, and multidisciplinary roles explicit.[6]
Shared-care models can extend capacity when role boundaries and escalation are clear. A Canadian pediatric rheumatology study compared key performance indicators for an advanced physiotherapist practitioner model using 138 practitioner-managed visits, 140 visits from the same center, and 11,431 eligible registry visits. The model met or exceeded the selected quality indicators. Retrospective comparison, a single-center setting, and model-specific metrics limit transfer. The evidence supports a local question: which activities require the specialist directly, which can be performed safely by a trained advanced role, and what triggers immediate escalation?[5]
Pharmacists may also strengthen continuity. A small before-and-after quality-improvement evaluation integrated a clinical pharmacist into a community rheumatology clinic and reported improvements in patient-reported disease impact, pain, and satisfaction at follow-up. The sample fell from 55 at three months to 25 at six months, with no concurrent control group, so the changes cannot be attributed confidently to the intervention. The study is most useful as feasibility evidence for medication education, reconciliation, monitoring, and access support within a governed team.[16]
An effective operating model needs a hub even when care remains distributed. The hub may be a primary-care clinician, specialty service, nurse coordinator, navigator, or other qualified role depending on the patient and setting. It should not absorb every decision. It should make the current question, decision owner, due date, pending evidence, and escalation route visible. Governance then reviews exceptions, capacity, equity, and safety at the system level.
Operating-system diagram
A coordinated autoimmune-care operating system
- Patient and supporterGoals, experience, access needs, informed choices
- Primary careLongitudinal synthesis, whole-person care, interim ownership
- Relevant specialtiesQualified assessment, organ-specific expertise, shared decisions
- Pharmacy and nursingMedication safety, education, monitoring, coordination
- Navigation and accessScheduling, coverage, travel, language, disability access
- Data and governanceTimeliness, experience, equity, standards, escalation, privacy
Digital and human infrastructure
Use technology to extend the relationship, not replace it.
Digital tools can support education, symptom tracking, preparation, self-management, remote contact, and shared visibility. They can also increase workload, create false reassurance, widen exclusion, and produce data that nobody reviews. The deciding factor is not whether an organization has an app or dashboard. It is whether the tool is linked to a defined human workflow.
In 14 qualitative interviews with stakeholders in rheumatic disease management, participants saw potential in digital patient education but described barriers involving content, individual needs, implementation, and trust. A hybrid approach was favored. The small expert sample does not measure patient outcomes, but it reinforces a practical design principle: pair validated digital content with opportunities for human clarification and adaptation.[9]
Workflow change is also visible in an interdisciplinary nurse-coordinated self-management intervention. Twelve health professionals from two Danish outpatient hospitals described training, time, and role adjustment as necessary to deliver the program, while perceiving improved coherence and continuous follow-up. These are qualitative feasibility findings rather than comparative outcomes. They demonstrate that coordination work must be resourced; it does not appear automatically because a new pathway is announced.[11]
Dashboards require the same discipline. In three focus groups with 13 clinicians at one university rheumatology clinic, participants said a rheumatoid arthritis outcomes dashboard could support trajectory review and communication. They also identified sparse data, time, refresh frequency, and the challenge of explaining outcomes as barriers. A dashboard that contains incomplete or stale measures may look authoritative while weakening decisions. Data quality, responsibility for review, and a response to concerning change belong in the product design.[14]
A pilot randomized study of 142 people with rheumatoid arthritis evaluated an eight-week mobile self-management program with a four-week follow-up. The intervention improved knowledge, depression, self-efficacy, physical activity, and perceived health, but did not improve disease activity or quality of life over the short study period. The single-center South Korean setting and pilot duration limit generalization. The mixed findings are useful: process and behavioral gains should not be described as clinical disease control, and a digital program should be measured across multiple outcomes.[15]
Leaders should define which data are entered by the patient, which arrive from clinical systems, how often a qualified person reviews them, what thresholds prompt contact, and what the person should do when symptoms worsen. Accessibility testing should cover language, disability, device, broadband, identity verification, proxy access, and digital literacy. A nondigital route must remain available. Consent and privacy should be proportionate to the sensitivity and purpose of the information.
Measurement
Measure whether the route produces a safe next step.
Awareness activity is easy to count: page views, event registrations, social engagement, handouts, and training attendance. These measures can describe reach, but they do not establish that a person was recognized, assessed, connected, or supported. A pathway dashboard should follow the open clinical question through to an owned resolution or a defined reassessment plan.
Start with a denominator that leaders can defend. The pilot population might be people in one entry setting who meet locally approved pattern-review criteria, not everyone with fatigue or every person receiving an autoimmune laboratory test. Define the starting event, exclusions, urgency groups, and the point at which the route is considered complete. Keep clinical decisions separate from performance targets so staff are not rewarded for more testing, more referrals, or more diagnoses.
Time should be measured by stage. Total elapsed time can hide whether the bottleneck is recognition, record assembly, clinical review, referral preparation, specialist availability, authorization, patient scheduling, or result follow-up. Report median and upper-tail performance because averages can conceal long waits. Pair time with safety and appropriateness: a faster referral is not an improvement if it is incomplete, mismatched, or disconnected from interim care.
Experience belongs beside utilization. Ask whether the person felt heard, understood why a test or referral was or was not recommended, knew who owned the next step, received help with a barrier, and knew how to return if the pattern changed. Review complaints and compliments, but do not depend on them alone. People harmed by prior dismissal may disengage without filing a complaint.
Structured data table
Proposed measurement specification for one pilot route
| Measure | Definition and denominator | Owner and cadence | Source and limitation |
|---|---|---|---|
| Pattern review reached | Eligible pilot cases receiving the approved longitudinal synthesis and qualified review | Primary-care operations; weekly during pilot | Template or audit. Depends on valid eligibility and documentation. |
| Stage-specific time | Median and 90th-percentile time from first documented pattern to review, referral decision, acceptance, and first contact | Analytics with clinical owner; monthly | Event timestamps. Missing or inconsistent starting events can bias results. |
| Referral readiness | Referrals containing the jointly approved, clinically justified information set | Referring and receiving services; monthly | Referral audit. Completeness does not establish appropriateness. |
| Accepted next step | Cases with an accepted appointment, explicit alternative plan, or documented decision not to refer, plus a named follow-up owner | Navigation or pathway owner; weekly | Queue and chart review. A scheduled visit is not completed care. |
| Completed first contact | Accepted referrals resulting in a completed first contact or clinically appropriate alternate plan | Access operations; monthly | Scheduling and partner confirmation. External data may be delayed. |
| Trust and clarity | People reporting they were heard, understood the plan, and knew whom to contact | Patient experience; monthly sample | Short survey and interviews. Nonresponse may exclude harmed patients. |
| Equity and access | Core measures stratified by locally governed demographic and access variables | Equity and analytics; monthly | Identity and access data. Requires privacy controls and small-cell suppression. |
| Balancing and safety | Urgent escalations, inappropriate referrals, unnecessary repetition, staff burden, privacy events, and unresolved cases | Clinical governance; weekly exceptions, monthly aggregate | Incident, queue, and audit data. Underreporting remains possible. |
A recurring review forum must be able to act on the data. During the pilot, a weekly exception review can resolve individual access failures while a monthly governance review addresses capacity, policy, and equity. Every exception should have a named action, due date, and verification method. Close the loop with participating staff and patients so they can see which changes followed their feedback.
Interpret improvement carefully. A rise in documented patterns may mean better recognition, broader eligibility, or documentation change. A temporary rise in referrals may expose previously unmet need. A lower decline rate may reflect better matching, but could also indicate restrictive referral behavior. Use run charts, case review, qualitative feedback, and balancing measures together before claiming success.
90-day plan
Pilot one complete route before expanding the campaign.
Select one entry setting where recurring or multisystem concerns are common enough to study and where qualified clinical leadership, referral partners, navigation, and measurement are available. Keep the pilot narrow. The goal is to learn whether the entire route works, not to create a universal autoimmune pathway in one quarter.
Clinical governance must approve the pattern-review triggers, urgent escalation, scope of assessment, referral requirements, patient communication, privacy controls, and reassessment process. The pilot should not introduce a broad laboratory panel, automated diagnosis, or population screening. It should improve synthesis, ownership, and connection around decisions that remain clinical.
Gantt timeline
Diagnostic-drift reduction pilot
Days 1–30: see the current route
- Name the executive sponsor, clinical governance lead, pilot owner, analytics lead, access partner, and patient advisors.
- Define the entry setting, eligible pattern, exclusions, urgent process, and limits of the pilot.
- Map the path from first concern through synthesis, review, referral, acceptance, interim care, and reassessment.
- Audit a sample of delays, repeated tests, declined referrals, unreviewed results, complaints, and successful connections.
- Agree on a concise pattern summary and clinically justified referral information set.
- Set measures, privacy controls, small-cell rules, baseline, and weekly exception review.
Days 31–60: test the complete connection
- Train the entry team with scenarios that include uncertainty, varied presentations, access barriers, and appropriate nonreferral.
- Use the pattern summary and qualified review process only within the approved pilot.
- Confirm referral fit and acceptance with receiving services rather than relying on order placement.
- Assign an interim owner for pending results, worsening concerns, and delays.
- Offer navigation for scheduling, coverage, travel, language, disability access, records, and digital needs.
- Review every decline, lost connection, urgent escalation, and privacy concern; modify the route when evidence supports change.
Days 61–90: stabilize and decide
- Compare stage-specific time, referral readiness, acceptance, completed contact, trust, and unresolved cases with baseline.
- Review clinical appropriateness, urgent events, unnecessary repetition, workload, and other balancing measures.
- Stratify results carefully and investigate differences with affected patients and communities.
- Update the trigger, summary, referral standard, capability map, scripts, and training.
- Document which controls are reliable, which remain provisional, and which require capacity or partnership.
- Sustain, adapt, pause, or expand through clinical governance rather than campaign momentum alone.
Leadership close
Awareness becomes care when uncertainty has an owner.
Autoimmune Awareness Month can focus attention on conditions that are complex, heterogeneous, and often distributed across clinical boundaries. The most credible executive response is not a promise that every case can be identified quickly. It is a commitment that meaningful patterns will be reviewed fairly, decisions will be clinically governed, referrals will be appropriate and confirmed, access barriers will be addressed, and a person will know who owns the next step.
Leaders should avoid simplistic solutions. A single laboratory result cannot represent every autoimmune condition. A symptom tracker cannot make a diagnosis. A referral does not guarantee access. A multidisciplinary roster does not guarantee coordination. A dashboard does not create action. Reliability comes from combining longitudinal synthesis, qualified judgment, explicit decision rights, verified capacity, navigation, respectful communication, human-supported technology, and recurring learning.
Executive action
Fund one 90-day diagnostic-drift reduction pilot in a defined entry setting. Require clinical governance, patient partnership, stage-specific measurement, confirmed next steps, interim ownership, equity review, and balancing measures before expansion.
Scholarly references
Peer-reviewed evidence, newest first
- Howren, A., Tran, Q. L., Sediqi, S., Hawa, S., Owens, D. K., Linos, E., Falasinnu, T. O., Chaichian, Y., & Simard, J. F. (2026). Effect of race and sex on lupus diagnosis in primary care: A randomized factorial survey study. PLOS ONE, 21(2), e0342328. https://doi.org/10.1371/journal.pone.0342328
- Alahmari, H., et al. (2026). Sources of knowledge, family and peer support, disclosure, and posting on social media platforms among patients with systemic autoimmune rheumatic diseases: A survey-based cross-sectional study. Journal of Patient Experience, 13, 1–9. https://doi.org/10.1177/23743735261415662
- Alkurdi, D., et al. (2026). Geographic disparities in accessibility to clinical studies for autoimmune skin disorders in the US: A retrospective review (2005–2024). Discover Public Health, 23(1), 1–11. https://doi.org/10.1186/s12982-026-01720-9
- Jensen, S. H. J., et al. (2025). Integrated rheumatology-gastroenterology clinic: An innovative organisation for patients with multiple autoimmune diseases. International Journal of Integrated Care, 25(4), 1–12. https://doi.org/10.5334/ijic.9292
- Herrington, J., et al. (2025). A Canadian advanced physiotherapist practitioner shared-care model in pediatric rheumatology offers safe and quality care in the management of juvenile idiopathic arthritis: Comparing key performance indicators with the PR-COIN registry. Children, 12(12), 1675. https://doi.org/10.3390/children12121675
- Chamorro-de-Vega, E., et al. (2025). New model of integrated care for patients with immune-mediated inflammatory diseases. International Journal of Integrated Care, 25(2), 1–14. https://doi.org/10.5334/ijic.7741
- Yang, J., et al. (2025). Real-world care patterns and specialist encounters of patients with systemic autoimmune rheumatic disease-related interstitial lung disease in the United States: A retrospective administrative claims database analysis. Rheumatology, 64(8), 4713–4721. https://doi.org/10.1093/rheumatology/keaf200
- Sloan, M., et al. (2025). “I still can’t forget those words”: Mixed methods study of the persisting impact on patients reporting psychosomatic and psychiatric misdiagnoses. Rheumatology, 64(6), 3842–3853. https://doi.org/10.1093/rheumatology/keaf115
- Lumma, F., Knitza, J., & Mühlensiepen, F. (2025). Potentials and barriers of digital patient education in rheumatic disease management: An exploratory qualitative interview study. Rheumatology International, 45(6), 148. https://doi.org/10.1007/s00296-025-05893-5
- Chaparro, C. A., Fernández-Ávila, D. G., Fuentes, Y., Ferreyra, L., Brance, M. L., & Muñoz, O. M. (2025). Usage patterns, trust generated, and influence of information in internet and social media on decision-making by patients diagnosed with rheumatic diseases in Latin America. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 18, 1–10. https://doi.org/10.1177/11795441251346815
- Madsen, C. M. T., et al. (2025). Health professionals’ experiences delivering an interdisciplinary nurse-coordinated self-management intervention for patients with inflammatory arthritis. Disability and Rehabilitation, 47(22), 5905–5913. https://doi.org/10.1080/09638288.2025.2472991
- Kremer, P., et al. (2025). Digital empowerment on hold: DiGA adoption gaps—A German national cross-sectional patient survey study. Rheumatology International, 45(7), 165. https://doi.org/10.1007/s00296-025-05922-3
- Liu, X., Patel, A. B., Seidel, J. E., Mosher, D. P., Hagens, J., & Marshall, D. A. (2025). Informing equitable access to care: A cross-sectional study of travel burden to primary and rheumatology care for people with rheumatoid arthritis. International Journal for Equity in Health, 24(1), 1–14. https://doi.org/10.1186/s12939-025-02439-w
- Nasrallah, C., et al. (2024). Using the technology acceptance model to assess clinician perceptions and experiences with a rheumatoid arthritis outcomes dashboard: Qualitative study. BMC Medical Informatics and Decision Making, 24, 140. https://doi.org/10.1186/s12911-024-02530-2
- Oh, H., Suh, C.-H., Kim, J.-W., & Boo, S. (2024). mHealth-based self-management program for patients with rheumatoid arthritis: A pilot randomized controlled study. Nursing & Health Sciences, 26(4), 1–10. https://doi.org/10.1111/nhs.13187
- Sandhu, V. K., Tuico, A., Hum, J., & Zachary, B. (2023). The impact of clinical pharmacist integration in a community rheumatology clinic. American Journal of Health-System Pharmacy, 80(10), 551–557. https://doi.org/10.1093/ajhp/zxac350
- Fuchs, F., et al. (2023). Diagnostic delay stages and pre-diagnostic treatment in patients with suspected rheumatic diseases before special care consultation: Results of a multicenter-based study. Rheumatology International, 43(3), 495–502. https://doi.org/10.1007/s00296-022-05223-z
- Fazaa, A., et al. (2022). Journey of rheumatoid arthritis patients in Tunisia: From symptoms to treatment. Archives of Rheumatology, 37(1), 85–93. https://doi.org/10.46497/ArchRheumatol.2022.8469
Authoritative resources
Campaign and public information
- Autoimmune Awareness Month: Why Awareness Matters, Autoimmune Association
- Autoimmune Awareness Month proclamations, Autoimmune Association